Antares Pharma (NASDAQ: ATRS) vs PetVivo (OTCMKTS: PETV) Stock Comparison

Antares Pharma (NASDAQ: ATRS - Get Rating) and Pet Vivo (OTCMKTS: PETV - Get Rating) are both small-cap medical organizations. In this article, we compare the two companies based on risk, institutional ownership, analyst recommendations, earnings, profitability, valuation, and returns.

Valuation and Earnings

Here is a comparison of Antares Pharma and Pet Vivo's gross revenue, profit per share (EPS), and valuation:

• Antares Pharma: $183.98 million gross revenue, price-to-sales ratio of 3.61, net income of $46.29 million, EPS of $0.27, P/E ratio of 14.44.
• Pet Vivo: $10,000 gross revenue, price-to-sales ratio of 1,612.88, net loss of $3.52 million, EPS of -$0.41, P/E ratio of -4.02.

Antares Pharma has higher revenue and profit than Pet Vivo. However, Pet Vivo has a lower price-to-earnings ratio, indicating it might be the more affordable stock currently.

Analyst Recommendations

Analysts have rated both stocks:

• Antares Pharma: 2 buy ratings, no sell or hold ratings, with a rating score of 3.00.
• Pet Vivo: 1 buy rating, no sell or hold ratings, with a rating score of 3.00.

Antares Pharma has a target price of $6.00, indicating a potential upside of 53.85%. Pet Vivo has a target price of $7.00, indicating a potential upside of 324.24%. This suggests analysts see greater upside in Pet Vivo.

Profitability

Comparison of profitability metrics:

• Antares Pharma: 25.16% net margins, 12.33% return on equity, 7.83% return on assets.
• Pet Vivo: -5,480.00% net margins, -100.42% return on equity, -70.55% return on assets.

Volatility and Risk

Both companies exhibit volatility in their stock prices:

• Antares Pharma: Beta of 1.48, indicating the stock price is 48% more volatile than the S&P 500.
• Pet Vivo: Beta of 1.9, indicating the stock price is 90% more volatile than the S&P 500.

Insider and Institutional Ownership

Ownership statistics for both companies:

• Antares Pharma: 48.6% institutional ownership, 5.9% insider ownership.
• Pet Vivo: 12.7% institutional ownership, 35.3% insider ownership.

Higher institutional ownership generally signals confidence from large investors. Antares Pharma has significantly more institutional ownership, while Pet Vivo has greater insider ownership.

Conclusion

Antares Pharma outperforms Pet Vivo on 9 out of the 13 comparison factors. However, with higher potential upside and strong insider ownership, Pet Vivo could be an intriguing speculative investment.

Company Profiles

Antares Pharma (Get Rating)

Antares Pharma, Inc. is a combination drug-device company involved in developing and commercializing self-administered parenteral pharmaceutical products. Key products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is based in Ewing, NJ.

Pet Vivo (Get Rating)

Pet Vivo Holdings, Inc. is a veterinary biotech and biomedical device company. It specializes in adapting human biotech and medical technology into products for the veterinary market. The company’s flagship product, Kush, is an intra-articular injection aimed at treating osteoarthritis in companion animals. Pet Vivo was founded in 2009 and is headquartered in Minneapolis, MN.

Top Medical Companies Worth Buying for Long-Term Investment

After the S&P 500 record's 10% year-to-date revision, there's no shortage of attractively valued stocks for long-term investors.

One area that is stacked with inexpensive stocks is healthcare. This sector currently has a forward price-to-earnings (P/E) ratio of 15.1, well below the average forward P/E ratio of 18.6 for the S&P 500 index.

1. CVS Health

CVS Health (CVS) is the second-largest health insurer in the world, just behind UnitedHealth Group. With the growing global healthcare demand, CVS is in a strong position to capitalize on the market's expansion through its Aetna business.

Analysts expect CVS to grow its earnings by 6% annually over the next five years. Investors can also benefit from CVS's 2.1% dividend yield, which is currently available at a forward P/E ratio of just 11.7, making CVS an attractive buy.

2. Amgen

Amgen (AMGN) is one of the world's top 10 pharmaceutical companies with a strong portfolio of drugs, including Prolia, Xgeva, and Otezla. Amgen's future growth looks promising, with 40 compounds currently in clinical trials.

Amgen's earnings are projected to grow by 7% annually over the next five years, and it offers a 3.3% dividend yield. With a forward P/E of 12.2, Amgen offers a compelling mix of growth and income potential.

3. Sanofi

Sanofi (SNY), based in France, is a major player in the pharmaceutical industry with a market cap of $122 billion. Sanofi's blockbuster drugs, such as Dupixent (co-owned with Regeneron), are driving growth, along with a robust pipeline of

Dicerna Pharmaceuticals Inc. [NASDAQ: DRNA] Stock Overview

Dicerna Pharmaceuticals Inc. stock closed at $37.92 with a trading volume of 7,906,174 shares. The company announced on November 22, 2021, that it is being investigated for its acquisition by Novo Nordisk. Shareholders will receive $38.25 per share they own.

Analyst Insights and Market Predictions

Wall Street experts have set a target price for DRNA at $34.96 per share, with a current recommendation of 2.20, indicating a Buy rating on a scale from 1 (Strong Buy) to 5 (Strong Sell).

Goldman Sachs maintains a Neutral stance on DRNA stock, while other firms have set price targets ranging from $32 to $38. The Average True Range (ATR) for DRNA is 1.75, and the Price-to-Sales ratio stands at 15.35 for the past year.

DRNA Stock Trading Performance

Over the past few months, DRNA has shown a 24.90% gain. In the last four weeks alone, shares have surged by 73.71%, with a total 66.10% rise over the past year. The stock has been highly active, with a daily trading volume of 7.9M shares, compared to its average of 1.39M shares.

Technical Analysis: RSI and Moving Averages

The Relative Strength Index (RSI) for DRNA currently sits at 88.55, indicating overbought conditions. The stock's 50-day moving average is $22.03, and the 200-day moving average is $27.44, suggesting bullish momentum in recent weeks.

Financial Performance Overview

Dicerna Pharmaceuticals reported a net margin of 68.62% and a Return on Invested Capital (ROIC) of 62.84. The company also has a Return on Equity (ROE) of 77.77%, and a Price-to-Free-Cash-Flow ratio of 344.41.

The company's Quick Ratio is 2.50, reflecting its ability to cover short-term obligations with its most liquid assets.

Earnings Per Share (EPS) Analysis

For the latest quarter, Dicerna Pharmaceuticals reported earnings of $0.49 per share, exceeding analysts' expectations of $0.03 per share, resulting in a surprise factor of 1,533.30%.

Institutional and Insider Ownership

Approximately 83.30% of DRNA stock is held by institutional investors. Major institutional holders include RTW Investments, BlackRock Inc., and State Street Corp. Institutional positions in DRNA increased in November, with 93 institutional investors adding 13.7M shares, while 112 investors reduced their holdings by 11.4M shares.